Hartman Institute for Therapeutic Organ Regeneration

Vaccination against tumor neovascularization: Promise and reality.

TitleVaccination against tumor neovascularization: Promise and reality.
Publication TypeJournal Article
Year of Publication2002
AuthorsRafii S
JournalCancer Cell
Volume2
Issue6
Pagination429-31
Date Published2002 Dec
ISSN1535-6108
KeywordsAnimals, Cancer Vaccines, Endothelium, Vascular, Genetic Engineering, Humans, Immune Tolerance, Neoplasms, Neovascularization, Pathologic, Vascular Endothelial Growth Factor Receptor-2
Abstract

Immunization against angiogenic-associated antigens selectively expressed on tumor vasculature provides for a novel strategy to block tumor growth. The feasibility of this approach has recently been borne out in several reports demonstrating that the protein or DNA of angiogenic molecules, such as VEGF-R2, can be used as vaccines to generate an effective cytotoxic T cell and antibody response against tumor vessels, thereby blocking tumor growth and metastasis.

DOI10.1016/s1535-6108(02)00208-8
Alternate JournalCancer Cell
PubMed ID12498709

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065